PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate
Executive Summary
Karuna Therapeutics plans to expand its development program for lead candidate KarXT beyond its current Phase II trial in schizophrenia. The series B financing follows a $42m series A in 2018.
You may also be interested in...
IPO Update: 28 Biopharma Companies Raise $3bn, Provide An Average 10% Return
Even though half of the drug developers that have gone public in the US during the first two quarters of the year are providing negative returns, the 13 companies trading in positive territory bring the class of 2019's average return to 10%.
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 10: Diversity, Equity And Inclusion
The acceleration of efforts to increase diversity among clinical trial subjects is expected to continue in 2023. Furthermore, many executives hope for greater inclusivity within companies, from new recruits to leadership.